Authors: Brodeur, GM Look, AT Shimada, H Hamilton, VM Maris, JM Hann, HW Leclerc, JM Bernstein, M Brisson, LC Brossard, J Lemieux, B Tuchman, M Woods, WG

Citation: Gm. Brodeur et al., Biological aspects of neuroblastomas identified by mass screening in Quebec, MED PED ONC, 36(1), 2001, pp. 157-159

Authors: Robaey, P Dobkin, P Leclerc, JM Cyr, F Sauerwein, C Theoret, Y

Citation: P. Robaey et al., A comprehensive model of the development of mental handicap in children treated for acute lymphoblastic leukaemia: A synthesis of the literature, INT J BEHAV, 24(1), 2000, pp. 44-58

Authors: Coppes, MJ Yanofsky, R Pritchard, S Leclerc, JM Howard, DR Perrotta, M Keays, S Pyesmany, A Dempsey, E Pratt, CB

Citation: Mj. Coppes et al., Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy, J PED H ONC, 21(4), 1999, pp. 274-283

Authors: Yotov, WV Hamel, H Rivard, GE Champagne, MA Russo, PA Leclerc, JM Bernstein, ML Levy, E

Citation: Wv. Yotov et al., Amplifications of DNA primase I (PRIMI) in human osteosarcoma, GENE CHROM, 26(1), 1999, pp. 62-69

Authors: Coppes, MJ Lau, R Ingram, LC Wiernikowski, JT Grant, R Howard, DR Perrotta, M Barr, R Dempsey, E Greenberg, ML Leclerc, JM

Citation: Mj. Coppes et al., Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderatelyto highly emetogenic chemotherapy, MED PED ONC, 33(2), 1999, pp. 99-105

Authors: Dubois, J Hershon, L Carmant, L Belanger, S Leclerc, JM David, M

Citation: J. Dubois et al., Toxicity profile of interferon alfa-2b in children: A prospective evaluation, J PEDIAT, 135(6), 1999, pp. 782-785